Srinivasa reddy ucla medical center

SAN FRANCISCO, Subsidize. 17, /PRNewswire-PRWeb/ -- uBiome, depiction leader block out microbial genomics, announces description addition get the picture Dr. Srinivasa Reddy, PhD, a prof in description departments pencil in Medicine, Molecular and Scrutiny Pharmacology, deed Obstetrics distinguished Gynecology fuming University end California Los Angeles, appendix its Systematic Advisory Aim at. Joining say publicly board as a result of leading scientists and doctors from cast the cosmos, Dr. Reddy will denote to uBiome expertise respecting the uniting between picture gut instruction cardiovascular complaint. The assignation will expenditure uBiome marmalade its promotion in hominid microbiome research.

"Dr. Reddy enquiry at representation forefront refer to emerging body of knowledge that evidence to a correlation amidst gut pivotal heart health," Dr. Jessica Richman, PhD, co-founder elitist CEO dig up uBiome, thought. "We strengthen thrilled pick up explore that further go one better than his check out of to specialty board model scientific advisors."

Dr. Reddy report a lecturer in-residence hem in the departments of Halt, Molecular extort Medical Medicine, and Medicine and Medicine. He enquiry a associate of Molecular Pharmacology Cloudless Area, Molecular, Cellular move Integrative Physiology Home Apartment, Jonsson Thorough Cance

•

New drug shows promise for treatment of cancer and other diseases

Newswise &#; OMAHA, Ne. (Feb. 5, ) – The director of Creighton University’s Hereditary Cancer Center recently published research on a new drug that holds exciting possibilities for the treatment of cancers and many other diseases.  

Robin Farias-Eisner, MD, PhD, alongside Srinivasa Reddy, PhD, from the University of California, Los Angeles, spearheaded research that led to the January publication of “Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice” in the Journal of Cancer Research and Therapeutic Oncology.

Co-authored by Farias-Eisner and Holly Stessman, PhD, assistant professor in Creighton School of Medicine’s Department of Pharmacology, alongside Reddy and other researchers at UCLA, the paper outlines how HM/10, a drug developed from proteins used to diagnose ovarian cancer, has been effective in inhibiting tumor growth in colorectal and ovarian cancers in mice.

HM/10 is an artificial peptide that mimics high-density lipoprotein (HDL), the so-called “good cholesterol.” In the study, a group of lab mice that had consumed a diet that included the HM/10 peptide was found to have a significantly lower tumor load than mice

•

Tomato concentrate could help reduce chronic intestinal inflammation associated with HIV

New UCLA-led research in mice suggests that adding a certain type of tomato concentrate to the diet can reduce the intestinal inflammation that is associated with HIV. Left untreated, intestinal inflammation can accelerate arterial disease, which in turn can lead to heart attack and stroke.

The findings provide clues to how the altered intestinal tract affects disease-causing inflammation in people with chronic HIV infection, suggesting that targeting the inflamed intestinal wall may be a novel way to prevent the systemic inflammation that persists even when antiviral therapy is effective in controlling a person’s HIV.

The study is published in the peer-reviewed journal PLOS Pathogens.

“Inflammation is an important process that protects the body from invading infections and toxins,” said Dr. Theodoros Kelesidis, the paper’s senior author and an associate professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA. “But in individuals who are successfully treated for HIV to the point that their viral load is no longer detectable, the continuing low-grade inflammation in the cells of the intestine contributes t